{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000206","form_type":"8-K","ticker":null,"cik":"0001792581","company_name":"Kiromic Biopharma, Inc.","filed_at":"2024-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.551138+00:00","generated_at":"2026-06-07T00:37:15.979761+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kiromic BioPharma issues $2M 25% senior secured convertible note due 2025","bullets":["Issued $2,000,000 25% senior secured convertible promissory note to an accredited investor, maturing January 8, 2025.","Note convertible into common stock at $2.50 per share, subject to 9.99% beneficial ownership limitation.","Secured by company's fixtures, equipment, and intellectual property; senior to all subordinated debt and equity.","Interest rate increases to 27% upon event of default; prepayment allowed without penalty."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000206","json":"https://secwatch.observer/filing/0001558370-24-000206.json","markdown":"https://secwatch.observer/filing/0001558370-24-000206.md","text":"https://secwatch.observer/filing/0001558370-24-000206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024000206/0001558370-24-000206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024000206/krbp-20240108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:37:15.979761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8abd471500935b00897f2980a5249e617fe5680c","claim":"Kiromic Biopharma, Inc. incurred convertible notes of $2,000,000 with an accredited investor at 25% per annum maturing January 8, 2025.","evidence_excerpt":"Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,000,000, bears interest at a rate of 25% per annum (the “Stated Rate”) and matures on January 8, 2025 (the “Maturity Date”), on which the principal balance and accrued but unpaid interest under the Note shall be due and payable.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024000206/0001558370-24-000206-index.htm","confidence":0.98,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$2,000,000"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Rate","value":"25% per annum"},{"label":"Maturity","value":"January 8, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"bf16158ddce32945acf97afb52f989600a2695c8","claim":"Kiromic Biopharma, Inc. entered into Note with an accredited investor valued at $2,000,000 (effective 2024-01-08).","evidence_excerpt":"On January 8, 2024, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,000,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024000206/0001558370-24-000206-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Value","value":"$2,000,000"},{"label":"Effective","value":"2024-01-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}